Literature DB >> 27365881

Unrecognized hemoglobin SE disease as microcytosis.

Avery Smith1, Barry Cooper1, Joseph Guileyardo1, Adan Mora1.   

Abstract

Hemoglobin SE disease was first described during the 1950s as a relatively benign microcytosis, but increasing prevalence has revealed a predisposition towards vasoocclusive sickling. Recognition of SE hemoglobinopathies' potential complications is crucial so medical measures can be utilized to avoid multiorgan injury.

Entities:  

Year:  2016        PMID: 27365881      PMCID: PMC4900779          DOI: 10.1080/08998280.2016.11929447

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  5 in total

Review 1.  Sickle cell-haemoglobin E (HbSE) compound heterozygosity: a clinical and haematological study.

Authors:  H H M Knox-Macaulay; M M Ahmed; D Gravell; S Al-Kindi; A Ganesh
Journal:  Int J Lab Hematol       Date:  2007-08       Impact factor: 2.877

Review 2.  Hemoglobin SE disease: a concise review.

Authors:  David Masiello; Matthew M Heeney; Adeboye H Adewoye; Shawn H Eung; Hong-Yuan Luo; Martin H Steinberg; David H K Chui
Journal:  Am J Hematol       Date:  2007-07       Impact factor: 10.047

Review 3.  Microcytic anemia.

Authors:  Thomas G DeLoughery
Journal:  N Engl J Med       Date:  2014-10-02       Impact factor: 91.245

4.  Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria.

Authors:  Kesinee Chotivanich; Rachanee Udomsangpetch; Kovit Pattanapanyasat; Wirongrong Chierakul; Julie Simpson; Sornchai Looareesuwan; Nicholas White
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 5.  Hemoglobin e syndromes.

Authors:  Elliott Vichinsky
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007
  5 in total
  1 in total

Review 1.  Manifestations of HbSE sickle cell disease: a systematic review.

Authors:  Ibrahim Khamees; Fateen Ata; Hassan Choudry; Ashraf T Soliman; Vincenzo De Sanctis; Mohamed A Yassin
Journal:  J Transl Med       Date:  2021-06-16       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.